Sweden · Delayed Price · Currency is SEK Medicover AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 delivered strong organic growth of 10.3% and margin expansion, with revenue at €624.2 million and adjusted EBITDA up 15.4%. India and Diagnostic Services led growth, while weather and geopolitical headwinds were effectively managed.
-
Strong organic growth, margin expansion, and disciplined investment have positioned the group for ambitious 2028 targets, with double-digit revenue and EBITDA growth expected. Key markets—Poland, Germany, Romania, and India—drive performance, supported by digital innovation and operational leverage.
Fiscal Year 2025
-
Double-digit revenue and profit growth in Q4 and FY 2025, with margin expansion and strong cash flow, driven by robust demand in core markets and successful integration of acquisitions. Achieved all three-year financial targets and set ambitious new goals for 2028.
-
Q3 saw strong organic growth, margin expansion, and robust cash flow, with both healthcare and diagnostics segments performing well. Guidance for the full year is unchanged, with expectations to beat revenue and EBITDA targets, despite some consumer caution and operational headwinds.
-
Q2 delivered 17% revenue growth, strong margin expansion, and tripled net profit, driven by organic growth across all markets and successful integration of recent acquisitions. Outlook remains positive, with targets expected to be exceeded and leverage to decline.
-
Strong Q1 growth and margin expansion are driven by recent capacity investments, robust performance in core markets, and strategic acquisitions. Focus remains on deepening market penetration, improving profitability, and accelerating Indian expansion through a planned local listing.
-
Record Q1 with double-digit organic growth, margin expansion, and strong cash flow. Poland and diagnostics led growth, while India rebounded after a weak quarter. Strategic acquisitions and robust outlook position the company to exceed 2025 targets.
Fiscal Year 2024
-
Delivered strong double-digit organic growth and margin expansion in both divisions for Q4 and FY2024, with Poland, Germany, and Romania leading performance. Cash flow and free cash flow surged, dividend increased 25%, and guidance for 2025 remains confident, with India and diagnostics expected to accelerate.
-
Q3 2024 saw robust organic revenue growth of 17.4% and record operating cash flow, with both Healthcare and Diagnostic Services delivering double-digit growth and margin expansion. Strategic investments, especially in India and Poland, are driving performance, and the group remains confident in meeting 2025 targets.
-
Q2 2024 saw 20% revenue growth (16% organic), strong cash generation, and margin expansion across divisions. Poland, Germany, and Romania led growth, while India is set to rebound. Confident in meeting 2025 targets, with continued investment and stable leverage.